ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Stock Information for ProMIS Neurosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference
ProMIS Neurosciences Announces Private Placement Financing
ProMIS Neurosciences Announces Private Placement Financing
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.